Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized.

Slides:

Advertisements

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Advertisements

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer Rodryg Ramlau, MD,

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Thymoma—A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD, Alexander Marx, MD, Philipp.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Perception of Lung Cancer among the General Population and Comparison with Other Cancers Julien Mazières, MD, PhD, Jean-Louis Pujol, MD, PhD, Nikos Kalampalikis,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Long-Term Results of a Phase II Trial of Induction Paclitaxel-Carboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation.

A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North.

Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non– Small-Cell Lung Cancer Grace K. Dy, MD, Paul N. Bogner, MD, Wei Tan,

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct )

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

A Functional Polymorphism on Chromosome 15q25 Associated with Survival of Early Stage Non–Small-Cell Lung Cancer Guang Jin, MD, PhD, Eun Young Bae, BS,

Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar.

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials Guillaume Mouillet, Msc, Elisabeth Monnet, MD, Bernard Milleron, MD, Marc Puyraveau, MSc, Elisabeth Quoix, MD, Philippe David, MD, Alain Ducoloné, MD, Olivier Molinier, MD, Gérard Zalcman, MD, PhD, Alain Depierre, MD, Virginie Westeel, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 5, Pages 841-849 (May 2012) DOI: 10.1097/JTO.0b013e31824c7d92 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Trial I design. Journal of Thoracic Oncology 2012 7, 841-849DOI: (10.1097/JTO.0b013e31824c7d92) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Trial II design. Journal of Thoracic Oncology 2012 7, 841-849DOI: (10.1097/JTO.0b013e31824c7d92) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Flow chart. Journal of Thoracic Oncology 2012 7, 841-849DOI: (10.1097/JTO.0b013e31824c7d92) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Kaplan–Meier survival plots according to pathologic response: (A) Overall survival (B) Disease-free survival. *Log-rank test. Journal of Thoracic Oncology 2012 7, 841-849DOI: (10.1097/JTO.0b013e31824c7d92) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions